Ionis Pharmaceuticals Licenses Alexander Disease Drug Zilganersen for International Markets

Ionis Pharmaceuticals has finalized a licensing agreement with Recordati for zilganersen, an experimental RNA-targeted medication for Alexander disease. This deal grants Recordati exclusive rights to develop and commercialize the treatment in all regions outside the United States. Alexander disease is a rare, severe neurological condition currently lacking approved disease-modifying therapies, making this development significant for future patient access.